Bio-Rad Laboratories Inc
NYSE: BIO-B · HEALTHCARE · MEDICAL DEVICES
Updated 2026-04-30
Bio-Rad Laboratories Inc (BIO-B) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for BIO-B.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
BIO-B historical valuation range
Where current P/E sits in BIO-B's own 5Y range.
BIO-B intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
BIO-B valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 10.75x
P/S Ratio — History
Current: 3.13x
Is BIO-B overvalued in 2026?
Bio-Rad Laboratories Inc (BIO-B) currently trades at $279.10 per share with a market capitalization of $8,082,274,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 51/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 10.8x, above its 5-year median of 9.9x. The PEG ratio of 1.21 points to a price that reasonably reflects expected earnings growth.
Looking at its own history, BIO-B is currently trading more expensive than 82% of the last 5Y on P/E. This places it in the 82th percentile of its historical range, a zone where forward returns have typically been muted.
Our discounted cash flow model estimates BIO-B's intrinsic value at $2,187.51 per share, against the current market price of $279.10. This implies a margin of safety of +86.51%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: BIO-B trades at a fair valuation on our framework, with a Smart Value Score of 51/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is BIO-B overvalued in 2026?
Based on a Smart Value Score of 51/100, BIO-B is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is BIO-B's fair value?
Our DCF model estimates BIO-B's intrinsic value at $2,187.51 per share, versus the current price of $279.10. This produces a margin of safety of +86.51%.
What P/E ratio does BIO-B trade at?
BIO-B trades at a P/E of 10.8x on trailing twelve-month earnings, compared to its 5-year median of 9.9x.
Is BIO-B a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 51/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does BIO-B's valuation compare to its history?
On P/E, BIO-B currently sits in the 82th percentile of its own 5Y range. That is historically expensive relative to where it has traded over the period.
What is BIO-B's Smart Value Score?
BIO-B's Smart Value Score is 51/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.